Citations

Showing 10 of 108152 citations.

The USD Science Gateway
Kleinsasser, Adison A., Pamidighantam, Sudhakar , Madison, Joseph D. , Christie, Marcus , Abeysinghe, Eroma, Pierce, Marlon , Jennewein, Douglas M. , Abeysinghe, Eroma, Marru, Suresh

Mayo Clinic

Proceedings of the Practice and Experience in Advanced Research Computing on Rise of the Machines (learning) | July 30, 2019 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1145/3332186.3333254 Get It

Rates of lobar atrophy in asymptomatic MAPT mutation carriers
Senjem, Matthew L. , Tosakulwong, Nirubol , Lesnick, Timothy G. , Brushaber, Danielle , Dheel, Christina, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Debra, Graff‐Radford, Jonathan, Graff‐Radford, Neill R., Jack, Clifford R. , Kremers, Walter K. , Rademakers, Rosa , Syrjanen, Jeremy A. , Boxer, Adam L. , Rosen, Howie, Kantarci, Kejal , Senjem, Matthew, Jack, Clifford R , Senjem, Matthew L , Kantarci, Kejal , Kremers, Walter K , Chen, Qin , Boeve, Bradley F. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Jones, David T. , Knopman, David S. , Lapid, Maria I. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | July 30, 2019 | Volume: 5 | Issue: 1 | Pages: 338-346

10.1016/j.trci.2019.05.010 | PMID 31388560 Get It

Abstract Introduction The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule‐associated protein tau ( MAPT ) mutation carriers. Methods MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor‐based morphometry with symmetric normalization algorithm. Results The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.
A Predictive Model for Nodal Metastases in Patients With Appendiceal Cancers
Day, Ryan W. , Stucky, Chee-Chee, Gray, Richard J. , Pockaj, Barbara A. , Wasif, Nabil , Pockaj, Barbara, Chang, Yu‐Hui

Mayo Clinic

Annals of Surgery | July 30, 2019 | Volume: 274 | Issue: 1 | Pages: 155-161

10.1097/sla.0000000000003501 | PMID 31361626 Get It

Background: Histologic subtypes of appendiceal cancer vary in their propensity for metastases to regional lymph nodes (LN). A predictive model would help direct subsequent surgical therapy. Methods: The National Cancer Database was queried for patients with appendiceal cancer undergoing surgery between 1998 and 2012. Multivariable logistic regression was used to develop a predictive model of LN metastases which was internally validated using Brier score and Area under the Curve (AUC). Results: A total of 21,647 patients were identified, of whom 9079 (41.9%) had node negative disease, 4575 (21.1%) node positive disease, and 7993 (36.9%) unknown LN status. The strongest predictors of LN positivity were histology (carcinoid tumors OR 12.78, 95% CI 9.01–18.12), increasing T Stage (T3 OR 3.36, 95% CI 2.52–4.50, T4 OR 6.30, 95% CI 4.71–8.42), and tumor grade (G3 OR 5.55, 95% CI 4.78–6.45, G4 OR 5.98, 95% CI 4.30–8.31). The coefficients from the regression analysis were used to construct a calculator that generated predicted probabilities of LN metastases given certain inputs. Internal validation of the overall model showed an AUC of 0.75 (95% CI 0.74–0.76) and Brier score of 0.188. Histology-specific predictive models were also constructed with an AUC that varied from 0.669 for signet cell to 0.75 for goblet cell tumors. Conclusions: The risk for nodal metastases in patients with appendiceal cancers can be quantified with reasonable accuracy using a predictive model incorporating patient age, sex, tumor histology, T-stage, and grade. This can help inform clinical decision making regarding the need for a right hemicolectomy following appendectomy.
Postoperative management of patients with spontaneous cerebrospinal fluid leak
Stevens, Shawn M. , Smith, Cody J. , Lawton, Michael

Mayo Clinic

Current Opinion in Otolaryngology & Head & Neck Surgery | July 30, 2019 | Volume: 27 | Issue: 5 | Pages: 361-368

10.1097/moo.0000000000000559 | PMID 31361610 Get It

Purpose of review To explore key management principles and outcomes following surgical intervention for spontaneous CSF leaks of the lateral skull base. Recent findings Outcomes following surgery for spontaneous CSF leaks of the lateral skull base depend on the surgical approach utilized. The approach reported most frequently in the literature is currently the middle fossa approach. Mean leak recurrence rates, regardless of approach, were approximately 6%. The lowest leak recurrence rates were associated with the combined middle cranial fossa-transmastoid approach. A multilayer closure was employed in all of the reviewed investigations, but the choice of reconstructive material did not significantly affect outcomes. Direct surgical complications rates, overall, were low at less than 2%. Meningitis, intracranial hemorrhage, and perioperative seizure activity were only rarely encountered. A concomitant diagnosis of idiopathic intracranial hypertension was found to be associated with increased rates of leak recurrence and sequential leak development at other skull base sites. Summary Postoperative management of patients with spontaneous CSF leaks of the lateral skull base has unique challenges. Observation of key treatment principles can lead to good outcomes and limit morbidity. A high index of suspicion should exist for concomitant idiopathic intracranial hypertension.
The Resilient Athlete: Lessons Learned in the Military
Barcia, Anthony M. , Shaha, James S., Tokish, John M.

Mayo Clinic

Sports Medicine and Arthroscopy Review | July 30, 2019 | Volume: 27 | Issue: 3 | Pages: 124-128

10.1097/jsa.0000000000000234 | PMID 31361723 Get It

Resilience, the capacity to recover from a setback or adversity, is a concept that has received considerable recent attention. An individual’s resilience predicts their life trajectory following stressful events and this has increasingly been shown in a wide variety of applications. Our understanding of the degree to which we can modify our resilience, and the optimal means to do so, remains in its infancy. The US military has embraced extensive efforts to quantify and build resilience in service members in an effort to preserve the fighting force. We specifically look at the understanding of resilience as it relates to the athletes in terms of competition and return from injury. This article explores the concept of resilience, the efforts to build resilience, lessons learned from the military and applications of the resilience concept to surgical and trauma patients.
Magnetic Resonance–guided High-intensity Focused Ultrasound (MRgHIFU) Virtual Treatment Planning for Abdominal Neuroblastoma Utilizing Retrospective Diagnostic 3D CT Images
Tung, Stephanie , Lamberti-Pasculli, Maria, Waspe, Adam C. , Pichardo, Samuel , Gerstle, Justin T. , Fahy, Aodhnait S.

Mayo Clinic

Journal of Pediatric Hematology/Oncology | July 30, 2019 | Volume: 41 | Issue: 7 | Pages: e443-e449

10.1097/mph.0000000000001563 | PMID 31449496 Get It

Magnetic resonance–guided high-intensity focused ultrasound (MRgHIFU) is a novel treatment for neuroblastoma using ultrasound-induced thermal ablation with real-time MR thermometry. It is unclear which patients would be amenable to MRgHIFU given the retroperitoneal location of many neuroblastomas within the smaller pediatric abdomen. In addition, planning relies on MR scans, which are not routine in the standard pediatric neuroblastoma workup. This study sought to demonstrate that neuroblastomas are targetable with MRgHIFU and available computed tomographic imaging could be utilized for MRgHIFU virtual treatment. Cross-sectional images of 88 pediatric abdominal neuroblastoma patients were retrospectively processed with custom software to be made compatible with the Sonalleve MRgHIFU platform. Targetability measured percent treatment to lesion volume, within adequate safety margins from critical structures. All images were successfully converted into treatment planning files. Median lesion size was 191±195 cm3 and depth was 29±17 mm. Up to 78 (85%) patients had targetable lesions with a median targetable volume of 15% and ranging up to 79%. Targetability was highest in superficial, right upper quadrant lesions >200 cm3, but limited by proximity to bowel and ribs. This study demonstrates the capacity for MRgHIFU to potentially treat the majority of abdominal neuroblastomas and the feasibility of using computed tomographic images for MRgHIFU virtual treatment planning.
Endovascular treatment decision in acute stroke: does physician gender matter? Insights from UNMASK EVT, an international, multidisciplinary survey
Ospel, Johanna M. , Kashani, Nima , Wilson, Alexis , Fischer, Urs , Sylaja, Pillai N., Turjman, Francis , Mitchell, Peter , Kim, Byung Moon , Cherian, Mathew , Heo, Ji Hoe , Baxter, Blaise, Podlasek, Anna , Foss, M , Menon, Bijoy K. , Hill, Michael D. , Saposnik, Gustavo , Ospel, Johanna Maria , Almekhlafi, Mohammed A , Hill, Michael D , Fischer, Urs , Campbell, Bruce , Yoshimura, Shinichi , Rabinstein, Alejandro A. , Almekhlafi, Mohammed , Demchuk, Andrew M. , Goyal, Mayank

Mayo Clinic

Journal of NeuroInterventional Surgery | July 30, 2019 | Volume: 12 | Issue: 3 | Pages: 256-259

10.1136/neurintsurg-2019-015003 | PMID 31363043 Get It

Background and purpose Differences in the treatment practice of female and male physicians have been shown in several medical subspecialties. It is currently not known whether this also applies to endovascular stroke treatment. The purpose of this study was to explore whether there are differences in endovascular treatment decisions made by female and male stroke physicians and neurointerventionalists. Methods In an international survey, stroke physicians and neurointerventionalists were randomly assigned 10 case scenarios and asked how they would treat the patient: (A) assuming there were no external constraints and (B) given their local working conditions. Descriptive statistics were used to describe baseline demographics, and the adjusted OR for physician gender as a predictor of endovascular treatment decision was calculated using logistic regression. Results 607 physicians (97 women, 508 men, 2 who did not wish to declare) participated in this survey. Physician gender was neither a significant predictor for endovascular treatment decision under assumed ideal conditions (endovascular therapy was favored by 77.0% of female and 79.3% of male physicians, adjusted OR 1.03, P=0.806) nor under current local resources (endovascular therapy was favored by 69.1% of female and 76.9% of male physicians, adjusted OR 1.03, P=0.814). Conclusion Endovascular therapy decision making between male and female physicians did not differ under assumed ideal conditions or under current local resources.
IGF-1/IGF-1R blockade ameliorates diabetic kidney disease through normalizing Snail1 expression in a mouse model
Dong, Rong , Yu, Jiali , Yu, Funxun, Qian, Qi , Zha, Yan , Yang, Song

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | July 30, 2019 | Volume: 317 | Issue: 4 | Pages: E686-E698

10.1152/ajpendo.00071.2019 | PMID 31361542 Get It

This study investigated the role of insulin-like growth factor-1/insulin-like growth factor-1 receptor (IGF-1/IGF-1R) in the genesis and progression of diabetic kidney disease (DKD) in a streptozotocin (STZ)-induced mouse diabetes model. We showed elevated IGF-1 expression in the DKD kidneys after 16 wk of diabetic onset. Intraperitoneal administration of IGF-1R inhibitor (glycogen synthase kinase-3β, GSK4529) from week 8 to week 16 postdiabetes induction ameliorated urinary albumin excretion and kidney histological changes due to diabetes, including amelioration of glomerulomegaly, inflammatory infiltration, and tubulointerstitial fibrosis. The GSK4529 treatment also attenuated alterations in renal tubular expression of E-cad and matrix protein fibronectin. Moreover, renal fibrosis in DKD (without treatment) was associated with Snail1 overexpression that was effectively prevented by IGF-1R inhibition. Further experiments in cultured renal epithelial cells (NRK) showed that IGF-1 silencing reproduced in vivo effects of IGF-1R inhibition with markedly attenuated Snail1 expression and near normalization of the Ecad1 and fibronectin expression pattern. Further Snail1 silencing prevented high-glucose-induced changes without affecting IGF-1 expression, consistent with Snail1 acting downstream to IGF-1. The antifibrotic effects were also shown with benazepril or insulin treatment but to a much lesser degree. In summary, in STZ-induced diabetic mice, activation of IGF-1 in diabetic kidneys induces fibrogenesis through Snail1 upregulation. The diabetes-related histological and functional changes, as well as fibrogenesis, can be attenuated by IGF-1/IGF-1R inhibition.
Prediction of Risk of Death for Patients Starting Dialysis
Anderson, Ryan T. , Cleek, Hailey, Pajouhi, Atieh, Bellolio, Fernanda , Mayukha, Ananya, Hickson, LaTonya J. , Feely, Molly A., Wilson, Michael E. , Connolly, Ryan M. Giddings, Erwin, Patricia J., Majzoub, Abdul M., Tangri, Navdeep , Hickson, LaTonya J , Bellolio, M Fernanda , Anderson, Ryan T., Hart, Allyson , Thorsteinsdottir, Bjorg

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 30, 2019 | Volume: 14 | Issue: 8 | Pages: 1213-1227

10.2215/cjn.00050119 | PMID 31362990 Get It

Background and objectives Dialysis is a preference-sensitive decision where prognosis may play an important role. Although patients desire risk prediction, nephrologists are wary of sharing this information. We reviewed the performance of prognostic indices for patients starting dialysis to facilitate bedside translation. Design, setting, participants, & measurements Systematic review and meta-analysis following the PRISMA guidelines. We searched Ovid MEDLINE, Ovid Embase, Ovid Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus for eligible studies of patients starting dialysis published from inception to December 31, 2018. Selection Criteria: Articles describing validated prognostic indices predicting mortality at the start of dialysis. We excluded studies limited to prevalent dialysis patients, AKI and studies excluding mortality in the first 1–3 months. Two reviewers independently screened abstracts, performed full text assessment of inclusion criteria and extracted: study design, setting, population demographics, index performance and risk of bias. Pre-planned random effects meta-analysis was performed stratified by index and predictive window to reduce heterogeneity. Results Of 12,132 articles screened and 214 reviewed in full text, 36 studies were included describing 32 prognostic indices. Predictive windows ranged from 3 months to 10 years, cohort sizes from 46 to 52,796. Meta-analysis showed discrimination area under the curve (AUC) of 0.71 (95% confidence interval, 0.69 to 073) with high heterogeneity ( I 2 =99.12). Meta-analysis by index showed highest AUC for The Obi, Ivory, and Charlson comorbidity index (CCI)=0.74, also CCI was the most commonly used (ten studies). Other commonly used indices were Kahn-Wright index (eight studies, AUC 0.68), Hemmelgarn modification of the CCI (six studies, AUC 0.66) and REIN index (five studies, AUC 0.69). Of the indices, ten have been validated externally, 16 internally and nine were pre-existing validated indices. Limitations include heterogeneity and exclusion of large cohort studies in prevalent patients. Conclusions Several well validated indices with good discrimination are available for predicting survival at dialysis start.
Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease
Sanchis, Irina M., Shukoor, Shehbaz, Irazabal, María V. , Madsen, Charles D. , Hogan, Marie C. , Zoghby, Ziad , Harris, Peter C. , Brown, Robert D., Torres, Vicente E. , El-Zoghby, Ziad , Harris, Peter C , Torres, Vicente E , Irazabal, Maria V , Hogan, Marie C , Chebib, Fouad T. , Huston, John

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 30, 2019 | Volume: 14 | Issue: 8 | Pages: 1151-1160

10.2215/cjn.14691218 | PMID 31362991 Get It

Background and objectives Intracranial aneurysm rupture is the most devastating complication of autosomal dominant polycystic kidney disease. Whether selective or widespread intracranial aneurysm screening is indicated remains controversial. Design, setting, participants & measurements Records of 3010 patients with autosomal dominant polycystic kidney disease evaluated at the Mayo Clinic between 1989 and 2017 were reviewed. Those who had presymptomatic magnetic resonance angiography screening were included. Results Ninety-four intracranial aneurysms were diagnosed in 75 of 812 (9%) patients who underwent magnetic resonance angiography screening. Sex, age, race, and genotype were similar in the groups with and without aneurysms; hypertension and history of smoking were more frequent in the aneurysm group. Twenty-nine percent of patients with aneurysms compared with 11% of those without aneurysms had a family history of subarachnoid hemorrhage ( P <0.001). Most aneurysms were small (median diameter =4 mm; range, 2–12 mm); 85% were in the anterior circulation. During a total imaging follow-up of 469 patient-years, de novo intracranial aneurysms were detected in five patients; eight intracranial aneurysms grew (median =2 mm; range, 1–3 mm). During a total clinical follow-up of 668 patient-years, seven patients had preemptive clipping or coil embolization; no intracranial aneurysms ruptured. During a total clinical follow-up of 4783 patient-years in 737 patients with no intracranial aneurysm detected on the first magnetic resonance angiography screening, two patients had an intracranial aneurysm rupture (0.04 per 100 person-years; 95% confidence interval, 0 to 0.10). The rate of intracranial aneurysm rupture in large clinical trials of autosomal dominant polycystic kidney disease was 0.04 per 100 patient-years (95% confidence interval, 0.01 to 0.06). Conclusions Intracranial aneurysms were detected by presymptomatic screening in 9% of patients with autosomal dominant polycystic kidney disease, more frequently in those with familial history of subarachnoid hemorrhage, hypertension, or smoking. None of the patients with and two of the patients without aneurysm detection on screening suffered aneurysmal ruptures. The overall rupture rate in our autosomal dominant polycystic kidney disease cohort was approximately five times higher than that in the general population.